drug
as of 2026-07-01Emraclidine
Emraclidine 10 mgEmraclidine 30 mgCVL-231Emraclidine 15 mgCVL-231 30 mg10 mg CVL-231 as IR formulation30 mg CVL-231 as slow-release MR formulation30 mg CVL-231 as medium release MR formulation
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Cerevel Therapeutics, LLC
8 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Investigational (via trials)
Trials
8
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
NCT07145918Phase 2Recruiting
A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia
NCT05443724Phase 2Completed
A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
NCT05227690Phase 2Completed
A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
NCT05227703Phase 2Completed
PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing
NCT04787302Phase 1Completed
Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia
NCT05245539Phase 1Completed
Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants
NCT05106309Phase 1Completed
A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia
NCT04136873Phase 1Completed
KOLs & investigators
3
Publications & congress
14
Novel pharmaceutical treatment approaches for schizophrenia: a systematic literature review.
European journal of clinical pharmacology · 2025 · high-value
Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial.
Lancet (London, England) · 2022 · high-value
Clinical Effects of Recently Developed Antipsychotic Drugs in Schizophrenia.
Central nervous system agents in medicinal chemistry · 2026
The mechanism of action of clozapine.
Journal of psychopharmacology (Oxford, England) · 2025
Xanomeline-Trospium for the Treatment of Schizophrenia.
Focus (American Psychiatric Publishing) · 2025
Muscarinic control of cardiovascular function in humans: a review of current clinical evidence.
Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2024
Design and Synthesis of Clinical Candidate PF-06852231 (CVL-231): A Brain Penetrant, Selective, Positive Allosteric Modulator of the M
Journal of medicinal chemistry · 2024
Understanding the Therapeutic Action of Antipsychotics: From Molecular to Cellular Targets With Focus on the Islands of Calleja.
The international journal of neuropsychopharmacology · 2024
PET imaging of M4 muscarinic acetylcholine receptors in rhesus macaques using [
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2024
Novel Compounds in the Treatment of Schizophrenia-A Selective Review.
Brain sciences · 2023
Characterization of a Novel M4 PAM PET Radioligand [11C]PF06885190 in Nonhuman Primates (NHP).
Molecules (Basel, Switzerland) · 2023
Psychopharmacology bulletin
Psychopharmacology bulletin · 2023
[Muscarinic M1 and/or M4 receptor agonists as potential novel treatments for psychoses].
Tijdschrift voor psychiatrie · 2023
A new cholinergic mechanism for antipsychotics: emraclidine and M4 muscarinic receptors.
Lancet (London, England) · 2022
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
company
trial
trial
trial
indication
indication
indication
indication
KOL
Julie Adams
personKOL score 11
Matthew Leoni, MD, MBA
personKOL score 4
Erica Koenig, PhD
personKOL score —